Nephrogenic Systemic Fibrosis (NSF) Treatment Market Report

Global and Region Nephrogenic Systemic Fibrosis (NSF) Treatment Market Demand & Opportunity Outlook 2022-2028

  • POSTDATE：Aug 03, 2022
  • PAGES：173
  • REPORT CODE：GMM1009628
  • REPORT SUMMARY
  • TABLE OF CONTENTS

  • Nephrogenic systemic fibrosis is a medical disorder which is extremely rare and which occurs among individuals who undergo exposure to an intravenous contrast material that contains gadolinium or in individuals that have reduced kidney function. Nephrogenic Systemic Fibrosis (NSF) Treatment involves treating the hardened or thickened fibrosis of the subcutaneous tissues, skin, or, at times, underlying skeletal muscles. Nephrogenic Systemic Fibrosis (NSF) Treatment is usually performed for legs and arms.

    The report details the trend, potential and market size of Nephrogenic Systemic Fibrosis (NSF) Treatment market, and analyzes the current situation and prospects of the market from both qualitative and quantitative aspects, which can be roughly divided into three parts.

    The first part (Chapter1-7) mainly covers the qualitative analysis of Nephrogenic Systemic Fibrosis (NSF) Treatmentmarket, defines the market attractiveness level of Nephrogenic Systemic Fibrosis (NSF) Treatment market through Porter's Five Forces Analysis, and summarizes the different factors in the overall environment through PEST analysis. Understand the distribution of industrial chain value in each link of industrial chain through the analysis of industrial chain structure. Thus estimate the market space of each link.

    The second part (Chapter8-12), based on the segmentation of Nephrogenic Systemic Fibrosis (NSF) Treatment industry, describes the types of Nephrogenic Systemic Fibrosis (NSF) Treatment market, the applications of major players and the market size, and deeply analyzes the current situation of the global Nephrogenic Systemic Fibrosis (NSF) Treatment market and the development prospects and opportunities of Nephrogenic Systemic Fibrosis (NSF) Treatment industry.

    The third part (Chapter14-15) includes the market positions of the major players and information on the market participants, which will help you gain a comprehensive understanding of the current competitive situation and potential growth opportunities in the market.

    As COVID-19 continues to impact the global economy in 2022, the report also considers the short - and long-term impacts of COVID-19 on the global Nephrogenic Systemic Fibrosis (NSF) Treatment market in Chapter 13.

    By Player:

    • Bausch Health

    • Novartis

    • Teva Pharmaceuticals

    • Johnson & Johnson

    • Merck

    • Pfizer

    • Sanofi

    • Allergan

    By Type:

    • Hemorrheologic Agents

    • Immunomodulatory Drug

    • Alkylating Agents

    • Kinase Inhibitors

    • Others

    By End-User:

    • Hospitals

    • Clinics

    • Others

    By Geography:

    • United States

    • Europe

    • China

    • Japan

    • India

    • South Korea

  • TABLE OF CONTENT

    1 Introduction

    • 1.1 Market Definition

    • 1.2 Market Segment Analysis

    • 1.3 Market Size 2022

    • 1.4 Nephrogenic Systemic Fibrosis (NSF) Treatment Market Outlook: Forecast for 2022 - 2028

    • 1.5 Pricing Analysis

    2 Executive Summary

    3 Nephrogenic Systemic Fibrosis (NSF) Treatment Market Lineage Outlook

    • 3.1 Parent Market Outlook

    • 3.2 Related/Ancillary Market Outlook

    • 3.3 Penetration & Growth Prospect Mapping, 2022

    4 Market Analysis Tools: Porter's Five Forces

    • 4.1 Supplier Power

    • 4.2 Buyer Power

    • 4.3 Substitution Threat

    • 4.4 Threat of New Entrants

    • 4.5 Competitive Rivalry

    5 Nephrogenic Systemic Fibrosis (NSF) Treatment Industry Analysis - PEST (Political & Legal, Economic, Social, and Technological)

    • 5.1 Political/Legal Landscape

    • 5.2 Economic Landscape

    • 5.3 Social Landscape

    • 5.4 Technology Landscape

    6 Nephrogenic Systemic Fibrosis (NSF) Treatment Market - Value Chain Analysis

    • 6.1 Industry's Value Chain Analysis

    • 6.2 Product Life Cycle

    • 6.3 User Perspective Analysis

    7 Region and Country-wise Nephrogenic Systemic Fibrosis (NSF) Treatment Market Analysis and Outlook to 2022

    • 7.1 Global Nephrogenic Systemic Fibrosis (NSF) Treatment Consumption (2017-2022)

    • 7.2 United States Nephrogenic Systemic Fibrosis (NSF) Treatment Consumption (2017-2022)

    • 7.3 Europe Nephrogenic Systemic Fibrosis (NSF) Treatment Consumption (2017-2022)

    • 7.4 China Nephrogenic Systemic Fibrosis (NSF) Treatment Consumption (2017-2022)

    • 7.5 Japan Nephrogenic Systemic Fibrosis (NSF) Treatment Consumption (2017-2022)

    • 7.6 India Nephrogenic Systemic Fibrosis (NSF) Treatment Consumption (2017-2022)

    • 7.7 South Korea Nephrogenic Systemic Fibrosis (NSF) Treatment Consumption (2017-2022)

    8 Region and Country-wise Nephrogenic Systemic Fibrosis (NSF) Treatment Market Analysis and Outlook to 2028

    • 8.1 Global Nephrogenic Systemic Fibrosis (NSF) Treatment Consumption Forecast (2022-2028)

    • 8.2 United States Nephrogenic Systemic Fibrosis (NSF) Treatment Consumption Forecast (2022-2028)

    • 8.3 Europe Nephrogenic Systemic Fibrosis (NSF) Treatment Consumption Forecast (2022-2028)

    • 8.4 China Nephrogenic Systemic Fibrosis (NSF) Treatment Consumption Forecast (2022-2028)

    • 8.5 Japan Nephrogenic Systemic Fibrosis (NSF) Treatment Consumption Forecast (2022-2028)

    • 8.6 India Nephrogenic Systemic Fibrosis (NSF) Treatment Consumption Forecast (2022-2028)

    • 8.7 South Korea Nephrogenic Systemic Fibrosis (NSF) Treatment Consumption Forecast (2022-2028)

    9 Global Nephrogenic Systemic Fibrosis (NSF) Treatment Market Outlook by Types and Applications to 2022

    • 9.1 Global Nephrogenic Systemic Fibrosis (NSF) Treatment Consumption and Growth Rate by Type (2017-2022)

      • 9.1.1 Global Hemorrheologic Agents Consumption and Growth Rate (2017-2022)

      • 9.1.2 Global Immunomodulatory Drug Consumption and Growth Rate (2017-2022)

      • 9.1.3 Global Alkylating Agents Consumption and Growth Rate (2017-2022)

      • 9.1.4 Global Kinase Inhibitors Consumption and Growth Rate (2017-2022)

      • 9.1.5 Global Others Consumption and Growth Rate (2017-2022)

    • 9.2 Global Nephrogenic Systemic Fibrosis (NSF) Treatment Consumption and Growth Rate by Application (2017-2022)

      • 9.2.1 Global Hospitals Consumption and Growth Rate (2017-2022)

      • 9.2.2 Global Clinics Consumption and Growth Rate (2017-2022)

      • 9.2.3 Global Others Consumption and Growth Rate (2017-2022)

    10 Global Nephrogenic Systemic Fibrosis (NSF) Treatment Market Outlook by Types and Applications to 2028

    • 10.1 Global Nephrogenic Systemic Fibrosis (NSF) Treatment Consumption Forecast and Growth Rate by Type (2022-2028)

      • 10.1.1 Global Hemorrheologic Agents Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.2 Global Immunomodulatory Drug Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.3 Global Alkylating Agents Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.4 Global Kinase Inhibitors Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.5 Global Others Consumption Forecast and Growth Rate (2022-2028)

    • 10.2 Global Nephrogenic Systemic Fibrosis (NSF) Treatment Consumption Forecast and Growth Rate by Application (2022-2028)

      • 10.2.1 Global Hospitals Consumption Forecast and Growth Rate (2022-2028)

      • 10.2.2 Global Clinics Consumption Forecast and Growth Rate (2022-2028)

      • 10.2.3 Global Others Consumption Forecast and Growth Rate (2022-2028)

    11 Global Nephrogenic Systemic Fibrosis (NSF) Treatment Import and Export Analysis (Top 5 Countries)

    • 11.1 Global Nephrogenic Systemic Fibrosis (NSF) Treatment Import by Region (Top 5 Countries) (2017-2028)

    • 11.2 Global Nephrogenic Systemic Fibrosis (NSF) Treatment Export by Region (Top 5 Countries) (2017-2028)

    12 Coronavirus Disease (COVID-19) Impact

    • 12.1 Industry Impact Analysis

    • 12.2 Nephrogenic Systemic Fibrosis (NSF) Treatment Market Outlook to 2028 - COVID-19 Affected Forecasts

    13 Competition Matrix

    • 13.1 Target Markets

    • 13.2 Comprehensive Analysis of Products in Competitive Markets

    14 Global Nephrogenic Systemic Fibrosis (NSF) Treatment Market Competitive Analysis

    • 14.1 Bausch Health

      • 14.1.1 Bausch Health Company Details

      • 14.1.2 Bausch Health Nephrogenic Systemic Fibrosis (NSF) Treatment Sales, Price, Value and Gross Profit (2017-2022)

      • 14.1.3 Bausch Health Nephrogenic Systemic Fibrosis (NSF) Treatment Product and Service

    • 14.2 Novartis

      • 14.2.1 Novartis Company Details

      • 14.2.2 Novartis Nephrogenic Systemic Fibrosis (NSF) Treatment Sales, Price, Value and Gross Profit (2017-2022)

      • 14.2.3 Novartis Nephrogenic Systemic Fibrosis (NSF) Treatment Product and Service

    • 14.3 Teva Pharmaceuticals

      • 14.3.1 Teva Pharmaceuticals Company Details

      • 14.3.2 Teva Pharmaceuticals Nephrogenic Systemic Fibrosis (NSF) Treatment Sales, Price, Value and Gross Profit (2017-2022)

      • 14.3.3 Teva Pharmaceuticals Nephrogenic Systemic Fibrosis (NSF) Treatment Product and Service

    • 14.4 Johnson & Johnson

      • 14.4.1 Johnson & Johnson Company Details

      • 14.4.2 Johnson & Johnson Nephrogenic Systemic Fibrosis (NSF) Treatment Sales, Price, Value and Gross Profit (2017-2022)

      • 14.4.3 Johnson & Johnson Nephrogenic Systemic Fibrosis (NSF) Treatment Product and Service

    • 14.5 Merck

      • 14.5.1 Merck Company Details

      • 14.5.2 Merck Nephrogenic Systemic Fibrosis (NSF) Treatment Sales, Price, Value and Gross Profit (2017-2022)

      • 14.5.3 Merck Nephrogenic Systemic Fibrosis (NSF) Treatment Product and Service

    • 14.6 Pfizer

      • 14.6.1 Pfizer Company Details

      • 14.6.2 Pfizer Nephrogenic Systemic Fibrosis (NSF) Treatment Sales, Price, Value and Gross Profit (2017-2022)

      • 14.6.3 Pfizer Nephrogenic Systemic Fibrosis (NSF) Treatment Product and Service

    • 14.7 Sanofi

      • 14.7.1 Sanofi Company Details

      • 14.7.2 Sanofi Nephrogenic Systemic Fibrosis (NSF) Treatment Sales, Price, Value and Gross Profit (2017-2022)

      • 14.7.3 Sanofi Nephrogenic Systemic Fibrosis (NSF) Treatment Product and Service

    • 14.8 Allergan

      • 14.8.1 Allergan Company Details

      • 14.8.2 Allergan Nephrogenic Systemic Fibrosis (NSF) Treatment Sales, Price, Value and Gross Profit (2017-2022)

      • 14.8.3 Allergan Nephrogenic Systemic Fibrosis (NSF) Treatment Product and Service

    15 Appendix


    TABLE OF CHARTS

    • Table Definition of Nephrogenic Systemic Fibrosis (NSF) Treatment

    • Figure Nephrogenic Systemic Fibrosis (NSF) Treatment Picture

    • Table Global Nephrogenic Systemic Fibrosis (NSF) Treatment Market Size and Forecast 2022 - 2028 (USD million)

    • Figure Global Nephrogenic Systemic Fibrosis (NSF) Treatment Market Size and Forecast 2022 - 2028 (USD million)

    • Figure Global Nephrogenic Systemic Fibrosis (NSF) Treatment Market: Year-over-year Growth 2022 - 2028 (%)

    • Table Parent Market Analysis

    • Figure Parent Market Price

    • Table Related/Ancillary Market Outlook Analysis

    • Table Supplier Power Analysis

    • Table Buyer Power Analysis

    • Table Substitution Threat Analysis

    • Table Threat of New Entrants Analysis

    • Table Competitive Rivalry Analysis

    • Figure Global Nephrogenic Systemic Fibrosis (NSF) Treatment Consumption by Country (2017-2022)

    • Figure United States Nephrogenic Systemic Fibrosis (NSF) Treatment Consumption and Growth Rate (2017-2022)

    • Table Europe Nephrogenic Systemic Fibrosis (NSF) Treatment Consumption and Growth Rate (2017-2022)

    • Figure China Nephrogenic Systemic Fibrosis (NSF) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Japan Nephrogenic Systemic Fibrosis (NSF) Treatment Consumption and Growth Rate (2017-2022)

    • Figure India Nephrogenic Systemic Fibrosis (NSF) Treatment Consumption and Growth Rate (2017-2022)

    • Figure South Korea Nephrogenic Systemic Fibrosis (NSF) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Global Nephrogenic Systemic Fibrosis (NSF) Treatment Consumption Forecast by Country (2022-2028)

    • Figure United States Nephrogenic Systemic Fibrosis (NSF) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Table Europe Nephrogenic Systemic Fibrosis (NSF) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure China Nephrogenic Systemic Fibrosis (NSF) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Japan Nephrogenic Systemic Fibrosis (NSF) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure India Nephrogenic Systemic Fibrosis (NSF) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure South Korea Nephrogenic Systemic Fibrosis (NSF) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Hemorrheologic Agents Consumption and Growth Rate (2017-2022)

    • Figure Global Immunomodulatory Drug Consumption and Growth Rate (2017-2022)

    • Figure Global Alkylating Agents Consumption and Growth Rate (2017-2022)

    • Figure Global Kinase Inhibitors Consumption and Growth Rate (2017-2022)

    • Figure Global Others Consumption and Growth Rate (2017-2022)

    • Figure Global Hospitals Consumption and Growth Rate (2017-2022)

    • Figure Global Clinics Consumption and Growth Rate (2017-2022)

    • Figure Global Others Consumption and Growth Rate (2017-2022)

    • Figure Global Hemorrheologic Agents Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Immunomodulatory Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Alkylating Agents Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Kinase Inhibitors Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Others Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Hospitals Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Clinics Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Others Consumption Forecast and Growth Rate (2022-2028)

    • Table Global Nephrogenic Systemic Fibrosis (NSF) Treatment Import by Region (Top 5 Countries) (2017-2028)

    • Table Global Nephrogenic Systemic Fibrosis (NSF) Treatment Export by Region (Top 5 Countries) (2017-2028)

    • Table Bausch Health (Foundation Year, Company Profile and etc.)

    • Table Bausch Health Nephrogenic Systemic Fibrosis (NSF) Treatment Sales, Price, Value and Gross Profit (2017-2022)

    • Table Bausch Health Nephrogenic Systemic Fibrosis (NSF) Treatment Product and Service

    • Table Novartis (Foundation Year, Company Profile and etc.)

    • Table Novartis Nephrogenic Systemic Fibrosis (NSF) Treatment Sales, Price, Value and Gross Profit (2017-2022)

    • Table Novartis Nephrogenic Systemic Fibrosis (NSF) Treatment Product and Service

    • Table Teva Pharmaceuticals (Foundation Year, Company Profile and etc.)

    • Table Teva Pharmaceuticals Nephrogenic Systemic Fibrosis (NSF) Treatment Sales, Price, Value and Gross Profit (2017-2022)

    • Table Teva Pharmaceuticals Nephrogenic Systemic Fibrosis (NSF) Treatment Product and Service

    • Table Johnson & Johnson (Foundation Year, Company Profile and etc.)

    • Table Johnson & Johnson Nephrogenic Systemic Fibrosis (NSF) Treatment Sales, Price, Value and Gross Profit (2017-2022)

    • Table Johnson & Johnson Nephrogenic Systemic Fibrosis (NSF) Treatment Product and Service

    • Table Merck (Foundation Year, Company Profile and etc.)

    • Table Merck Nephrogenic Systemic Fibrosis (NSF) Treatment Sales, Price, Value and Gross Profit (2017-2022)

    • Table Merck Nephrogenic Systemic Fibrosis (NSF) Treatment Product and Service

    • Table Pfizer (Foundation Year, Company Profile and etc.)

    • Table Pfizer Nephrogenic Systemic Fibrosis (NSF) Treatment Sales, Price, Value and Gross Profit (2017-2022)

    • Table Pfizer Nephrogenic Systemic Fibrosis (NSF) Treatment Product and Service

    • Table Sanofi (Foundation Year, Company Profile and etc.)

    • Table Sanofi Nephrogenic Systemic Fibrosis (NSF) Treatment Sales, Price, Value and Gross Profit (2017-2022)

    • Table Sanofi Nephrogenic Systemic Fibrosis (NSF) Treatment Product and Service

    • Table Allergan (Foundation Year, Company Profile and etc.)

    • Table Allergan Nephrogenic Systemic Fibrosis (NSF) Treatment Sales, Price, Value and Gross Profit (2017-2022)

    • Table Allergan Nephrogenic Systemic Fibrosis (NSF) Treatment Product and Service


Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.

CONTACT US